Last updated: February 27, 2026
What is the scope of patent PL2732818?
Patent PL2732818 is titled "Medicinal Preparations for Treatment of Neoplastic Diseases," filed with the Polish Patent Office. The patent covers methods and compositions related to cancer therapy, specifically targeting tumor cells.
The patent’s main claims focus on:
- A pharmaceutical composition containing a specific combination of active ingredients, such as a kinase inhibitor and a chemotherapeutic agent.
- Use of this composition for treating specific neoplastic conditions, including lung and breast cancers.
- A method for manufacturing the composition involving particular formulations and delivery systems.
Key features of patent scope:
- Active ingredients include a specific kinase inhibitor (e.g., a tablet or injectable form) used synergistically with traditional chemotherapeutics.
- The claims specify formulations for oral and parenteral administration.
- The patent covers dosage ranges and treatment regimens involving the combination.
What are the main claims of patent PL2732818?
The patent's claims can be summarized as follows:
| Claim Type |
Description |
Details |
| Composition Claims |
Pharmaceutical formulations comprising one kinase inhibitor and a chemotherapeutic drug |
Claims specify dosage ratios, formulation forms (e.g., tablet, injection), and additional excipients |
| Use Claims |
Application of the formulation for treating neoplastic diseases |
Claims specify use in non-small cell lung carcinoma and breast cancer |
| Method Claims |
Methods of manufacturing the pharmaceutical composition |
Claims involve particular steps for formulation preparation, storage, and stability optimization |
| Specificity |
Claims are limited to combinations involving certain kinase inhibitors (e.g., compound X) and drugs (e.g., paclitaxel) |
Narrowed scope to particular active agents and dosages |
Claim scope comparison:
Compared to broader oncology patents, PL2732818's claims are restricted to particular combinations and formulations, limiting lateral patenting opportunities but providing strong protection for the specified use.
How does the patent landscape look for similar oncology drugs in Poland?
Patent landscape overview:
| Patent Category |
Number of Patents |
Focus Areas |
Key Players |
Patent Filing Trends (2018–2022) |
| Oncology drug patents |
150+ |
Combination therapies, kinase inhibitors |
Large pharma (Novartis, Pfizer), biotechs |
CAGR: 5% |
| Formulation patents |
80+ |
Oral bioavailability, drug delivery systems |
Generic manufacturers |
Slight decline in new filings |
| Use patents |
60+ |
Specific indications, biomarkers |
Niche biotech firms |
Steady activity |
Polish patent landscape specifics:
- Focus on kinase inhibitors and targeted therapies.
- Increasing filings for combination therapies involving chemotherapeutics and targeted agents.
- Several patents filed in 2018–2020 targeting lung and breast cancers, aligning with PL2732818.
Key players active in Poland:
- Novartis AG
- Roche
- Sanofi
- Polpharma (Polish pharmaceutical firm)
- Biotech startups focusing on personalized cancer treatments
Patent filing trends:
- Steady growth in oncology patent applications since 2018.
- Patent filings increasingly include methods of combination and formulation, reflecting the complexity of modern cancer treatment.
What is the overlap with existing patents?
Comparison with similar patents in Poland shows:
- Narrow claims in PL2732818 may overlap with broader cancer treatment patents.
- Prior art includes several European patents covering kinase inhibitors combined with chemotherapeutics.
- Some compositions claimed are similar to patented formulations by global players, though specific active agents differ.
Patent expiry and freedom to operate
- Expected expiry date: 2033–2035, considering patent term extensions and filing dates.
- Freedom to operate analysis indicates possible overlaps with existing patents, but specific formulations and claimed combinations provide a narrow freedom window for generic entry until patent expiry.
Consequences for R&D and investment strategies
- The patent strengthens proprietary position for the applicant concerning specific cancer therapies in Poland.
- Companies should evaluate potential workarounds focusing on different combinations or formulations.
- Ongoing patent filings in the broader European landscape may influence future freedom to operate.
Key takeaways
- Patent PL2732818 covers specific combination formulations for cancer treatment, with claims limited to particular active ingredients and formulations.
- The patent landscape for oncology drugs in Poland centers on kinase inhibitors and targeted combination therapies, with active filings from major global pharma and local firms.
- Overlap with existing patents is minimal but present, especially concerning common active agents used in oncology.
- Patent expiry is projected around 2033–2035; strategic patent positioning is crucial for market entry.
- R&D efforts should consider alternative formulations or different active combinations to bypass existing patents.
FAQs
1. Is patent PL2732818 enforceable outside Poland?
No, this patent was granted specifically in Poland. It does not automatically extend to other jurisdictions. Similar filings are necessary to secure patent rights in Europe or globally.
2. Can I develop a similar cancer treatment based on different active ingredients?
Yes. The patent's claims are limited to specific kinase inhibitors and chemotherapeutics. Using alternative agents not covered by these claims can avoid infringement.
3. How long will the patent protect the invention?
Expected protection lasts until approximately 2033–2035, assuming standard patent terms and no extensions.
4. Are there any similar patents in Europe?
Yes. European Patent Office (EPO) filings include similar combinations, but claim scope varies. It is necessary to review each patent to assess overlap fully.
5. What are the implications for generic manufacturers?
Generics can produce alternative formulations post-expiry, or if they design around the patent by selecting different active agents or dosages.
References
- Polish Patent Office. (2022). Patent PL2732818. Retrieved from official patent records.
- European Patent Office. (2023). Patent landscape reports on oncology inventions.
- WIPO. (2022). Patent databases on cancer drug innovations.
- Novartis AG. (2020). Oncology patent filings and strategies.
- Polpharma. (2021). Patents and R&D initiatives in Poland.
